Key factors
sym | CHMA |
exch | US |
MCap | 237.81M |
Beta | 1.256 |
EPS | -1.57 |
Div date | 0000-00-00 |
Yesterday
sym | CHMA |
exch | US |
close | 3.76 |
50 Day MA | 4.354 |
200 Day MA | 3.864 |
Target Price | 9.1 |
Market Cap Mln | 237.81 |
Share statistics
Shares Outstanding | 63.24M |
Shares Float | 33.80M |
Percent Institutions | 76.11 |
PercentInsiders | 0.581 |
SharesShort | 756.01K |
Short Ratio | 0.62 |
Shares Short Prior Month | 849.92K |
Short Percent | 2.239 |
Income
Revenue TTM | 3030.0K |
Revenue Per Share TTM | 0.053 |
Gross Profit TTM | 1045.0K |
EBITDA | -33.1M |
Diluted Eps TTM | -1.57 |
earning
Operating Margin TTM | -24.0 |
EPS Estimate Current Quarter | -0.31 |
EPS Estimate Current Year | -1.27 |
EPS Estimate Next Quarter | -0.31 |
EPS Estimate Next Year | -0.71 |
Earnings Share | -1.57 |
Dividend
Dividend Date | 0000-00-00 |
Last Split Date | 0000-00-00 |
business
Enterprise Value Revenue | 52.43 |
Book Value /share | 1.084 |
Price Book MRQ | 3.793 |
Price Sales TTM | 71.22 |
ReturnOnAssetsTTM | -0.37 |
ReturnOnEquityTTM | -1.33 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Pharmaceuticals |
Gic Sector | Health Care |
Gic Sub Industry | Pharmaceuticals |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US16706W1027 |
CIK | 1339469 |
Code | CHMA |
CUSIP | 16706W102 |
Employer Id Number | 76-0722250 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2021-11-14 |
is Delisted | 1 |
Delisted Date | 2021-09-15 |
Home Category | Domestic |
info
Fiscal Year End | December |
Full Time Employees | 84.0 |
IPODate | 2015-07-16 |
International Domestic | Domestic |
MostRecent Quarter | 2021-03-31 |
Contact
Name | Chiasma Inc |
Address | Building C East, Needham, MA, United States, 02494 |
Country Name | USA |
Phone | 617 928 5300 |
Web URL | www.chiasma.com |
Logo URL | /img/logos/US/CHMA.png |
Chiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.